Henri Versteeg
Professor Internal Medicine
- Name
- Prof.dr. H.H. Versteeg
- Telephone
- +31 71 526 3872
- h.h.versteeg@lumc.nl
- ORCID iD
- 0000-0003-4294-175X
Henri Versteeg is a professor of Thrombosis and Haemostasis and member of the management team of the Department of Internal Medicine at the Leiden University Medical Center. He is the recipient of a number of prestigious grants and awards, based on his work on cancer and blood coagulation, such as an NWO-VENI and an NWO-VIDI grant.
More information about Henri Versteeg
Henri Versteeg is a professor of Thrombosis and Haemostasis and member of the management team of the Department of Internal Medicine at the Leiden University Medical Center. He is the recipient of a number of prestigious grants and awards, based on his work on cancer and blood coagulation, such as an NWO-VENI and an NWO-VIDI grant.
Cancer and blood clotting
In cancer patients, blood clotting is hyper-activated leading to increased risk of venous thrombosis and pulmonary embolism (collectively referred to as VTE). VTE reduces quality of life, may interrupt cancer treatment and is the second leading cause of death in cancer patients. As it is currently unclear which biological processes induce VTE in cancer patients, it is impossible to predict which cancer patients should be treated with anticoagulants to prevent VTE. Therfore Versteeg aims to unravel which biological factors impact cancer-associated VTE and develop tools to predict which cancer patients have an increased risk of VTE.
Conversely, hyper-activation of the blood clotting system also promotes cancer progression. Tumor cells express blood clotting proteins that prime tumors to grow and disseminate but the mechanisms that dictate coagulation-dependent cancer progression are ill-defined. Therefore Versteeg endeavours to uncover the role of blood clotting in cancer, with specific focus on the molecular and cellular mechanisms.
Academic career
Versteeg received an MSc degree in biology at Utrecht University and successfully finished his PhD studies at the University of Amsterdam, with a thesis entitled; He continued his research on blood coagulation and cancer, first at the Scripps Research Institute and subsequently at Leiden University Medical Center. In 2015, he was appointed full professor in Thrombosis and Haemostasis. The title of his inaugural speech was 'Over bloedbanen en bloedbaden' (Dutch).
Versteeg has published more than 100 scientific research papers, review papers and editorials in journals such as Nature Medicine, Proceedings of the National Academy of Sciences USA, Circulation Research and Blood. He is a member of several selection committees among which those for the NWO-VENI, NWO-VIDI and Agence National de Recherche programs. He was also a member of selection commitees for international congresses, e.g. those of International Society of Thrombosis and Hemostasis and the American Society of Hematology. He has also served in international advisory boards.
Currently, Versteeg is the Editor-in-chief of ‘Thrombosis Research and an editorial board member of ‘Carcinogenesis’ and ‘Journal of Visualized Experiments’.
Prizes and honourable appointments
Henri Versteeg is the recipient of a number of presigious grants and awards such as an NWO Talent stipendium, an NWO-VENI grant and an NWO-VIDI grant. Hij has also received the Novo Nordisk Haemostasis Award and the Marie Parijs award for excellent translational research.
Professor Internal Medicine
- Faculteit Geneeskunde
- Divisie 2
- Interne Geneeskunde
- A.I.G. algemeen
- Chu, G.R.; Seelig, J.; Cannegieter, S.C.; Gelderblom, H.; Hovens, M.M.C.; Huisman, M.V.; Hulle, T. van der; Trines, S.A.; Vlot, A.J.; Versteeg, H.H.; Hemels, M. & Klok, F.A. (2023), Thromboembolic and bleeding complications during interruptions and after discontinuation of anticoagulant treatment in patients with atrial fibrillation and active cancer, Thrombosis Research: Vascular Obstruction, Hemorrhage and Hemostasis 230: 98-104.
- Kapteijn, M.Y.; Kaptein, F.H.J.; Stals, M.A.M.; Klaase, E.E.; Eijk, R. van; Ruano, D.; Duinen, S.G. van; Cannegieter, S.C.; Taphoorn, M.J.B.; Dirven, L.; Koekkoek, J.A.F.; Klok, F.A.; Versteeg, H.H.; Buijs, J.T. & Garcia-Ortiz, I. (2023), Targeted DNA sequencing to identify genetic aberrations in glioblastoma that underlie venous thromboembolism; a cohort study, Thrombosis Research: Vascular Obstruction, Hemorrhage and Hemostasis 221: 10-18.
- Kaptein, F.H.J.; Stals, M.A.M.; Evenhuis, R.E.; Gelderblom, H.; Huisman, M.V.; Karis, D.S.A.; Noten, R.W.D.; Cannegieter, S.C.; Speetjens, F.M.; Verschoor, A.J.; Versteeg, H.H.; Sande, M.A.J. van de & Klok, F.A. (2023), Risk of venous thromboembolism and major bleeding in the clinical course of osteosarcoma and Ewing sarcoma, Thrombosis Research: Vascular Obstruction, Hemorrhage and Hemostasis 221: 19-25.
- Akolawala, Q.; Keuning, F.; Rovituso, M.; Burik, W. van; Wal, E. van der; Versteeg, H.H.; Rondon, A.M.R. & Accardo, A. (2023), Micro-Vessels-Like 3D Scaffolds for Studying the Proton Radiobiology of Glioblastoma-Endothelial Cells Co-Culture Models, Advanced Healthcare Materials.
- Dorst, D. van; Buijs, S.M.; Kruip, M.J.H.A.; Akker, R.F.P. van den; Cheung, K.L.; Porrazzo, R.; Oomen-de Hoop, E.; Jager, A.; Koolen, S.L.; Versmissen, J.; Danser, J.A.H.; Versteeg, H.H.; Bos, M.H.A. & Mathijssen, R.H. (2023), Association between tamoxifen and endoxifen plasma levels and clotting proteins in patients with primary breast cancer, Annals of Oncology 34: S295-S295.
- Anijs, R.J.S.; Chen, Q.; Hulle, T. van der; Versteeg, H.H.; Klok, F.A.; Lijfering, W.M. & Cannegieter, S.C. (2023), Venous and arterial thromboembolism after colorectal cancer in the Netherlands: Incidence, predictors, and prognosis, Thrombosis Research: Vascular Obstruction, Hemorrhage and Hemostasis 229: 90-98.
- Kapteijn, M.Y.; Zwaan, S.; Linden, E. ter; Laghmani, E.; Akker, R.F.P. van den; Rondon, A.M.R.; Zanden, S.Y. van der; Neefjes, J.; Versteeg, H.H. & Buijs, J.T. (2023), Temozolomide and Lomustine Induce Tissue Factor Expression and Procoagulant Activity in Glioblastoma Cells In Vitro, Cancers 15(8).
- Chu, G.R.; Seelig, J.; Cannegieter, S.C.; Gelderblom, H.; Hovens, M.M.C.; Huisman, M.V.; Hulle, T.V.; Trines, S.A.; Vlot, A.J.; Versteeg, H.H.; Hemels, M.E.W. & Klok, F.A. (2023), Atrial fibrillation in cancer: thromboembolism and bleeding in daily practice, Research and Practice in Thrombosis and Haemostasis 7(2).
- Kapteijn, M.Y.; Lanting, V.R.; Kaptein, F.H.J.; Guman, N.A.M.; Laghmani, E.H.; Kuipers, T.B.; Mei, H.L.; Goeman, J.J.; Mulder, F.I.; Duinen, S.G. van; Taphoorn, M.J.B.; Dirven, L.; Broekman, M.L.D.; Es, N. van; Klok, F.A.; Koekkoek, J.A.F.; Versteeg, H.H. & Buijs, J.T. (2023), RNA-sequencing to discover genes and signaling pathways associated with venous thromboembolism in glioblastoma patients: A case-control study, Thrombosis Research: Vascular Obstruction, Hemorrhage and Hemostasis 232: 27-34.
- Buijs, J.T.; Unlu, B.; Laghmani, E.H.; Heestermans, M.; Vlijmen, B.J.M. van & Versteeg, H.H. (2023), Assessment of breast cancer progression and metastasis during a hypercoagulable state induced by silencing of antithrombin in a xenograft mouse model, Thrombosis Research: Vascular Obstruction, Hemorrhage and Hemostasis 221: 51-57.
- Anijs, R.J.S.; Nguyen, Y.N.; Cannegieter, S.C.; Versteeg, H.H. & Buijs, J.T. (2023), MicroRNAs as prognostic biomarkers for (cancer-associated) venous thromboembolism, Journal of Thrombosis and Haemostasis 21(1): 7-17.
- Anijs, R.J.S.; Laghmani, E.; Unlu, B.; Kielbasa, S.M.; Mei, H.L.; Cannegieter, S.C.; Klok, F.A.; Kuppen, P.J.K.; Versteeg, H.H. & Buijs, J.T. (2022), Tumor-expressed microRNAs associated with venous thromboembolism in colorectal cancer, Research and Practice in Thrombosis and Haemostasis 6(5).
- Dolleman, S.C.; Agten, S.M.; Spronk, H.M.H.; Hackeng, T.M.; Bos, M.H.A.; Versteeg, H.H.; Zonneveld, A.J. van & Boer, H.C. de (2022), Thrombin in complex with dabigatran can still interact with PAR-1 via exosite-I and instigate loss of vascular integrity, Journal of Thrombosis and Haemostasis 20(4).
- Kaptein, F.H.J.; Stals, M.A.M.; Kapteijn, M.Y.; Cannegieter, S.C.; Dirven, L.; Duinen, S.G. van; Eijk, R. van; Huisman, M.V.; Klaase, E.E.; Taphoorn, M.J.B.; Versteeg, H.H.; Buijs, J.T.; Koekkoek, J.A.F. & Klok, F.A. (2022), Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma, Journal of Thrombosis and Haemostasis 20(7).
- Akolawala, Q.; Rovituso, M.; Versteeg, H.H.; Rondon, A.M.R. & Accardo, A. (2022), Evaluation of proton-induced DNA damage in 3D-engineered glioblastoma microenvironments, ACS Applied Materials and Interfaces 14(18): 20778-20789.
- Unlu, B.; Kocaturk, B.; Rondon, A.M.R.; Lewis, C.S.; Swier, N.; Akker, R.F.P. van den; Krijgsman, D.; Noordhoek, I.; Blok, E.J.; Bogdanov, V.Y.; Ruf, W.; Kuppen, P.J.K. & Versteeg, H.H. (2022), Integrin regulation by tissue factor promotes cancer stemness and metastatic dissemination in breast cancer, Oncogene 41(48): 5176-5185.
- Touw, C.E.; Nemeth, B.; Rondon, A.M.R.; Adrichem, R.A. van; Lisman, T.; Versteeg, H.H.; Schipper, I.B.; Nelissen, R.G.H.H.; Bos, M.H.A. & Cannegieter, S.C. (2022), Lower-leg injury and knee arthroscopy have distinct effects on coagulation, Blood Advances 6(17): 5232-5243.
- Versteeg, M.; Bressers, G.; Wijnen-Meijer, M.; Ommering, B.W.C.; Beaufort, A.J. de & Steendijk, P. (2021), What were you thinking?, Teaching and Learning in Medicine 33(5).
- Hanna-Sawires, R.G.; Groen, J.V.; Hamming, A.; Tollenaar, R.A.E.M.; Mesker, W.E.; Luelmo, S.A.C.; Vahrmeijer, A.L.; Bonsing, B.A.; Versteeg, H.H.; Klok, F.A. & Mieog, J.S.D. (2021), Incidence, timing and risk factors of venous thromboembolic events in patients with pancreatic cancer, Thrombosis Research: Vascular Obstruction, Hemorrhage and Hemostasis 207: 134-139.
- Lewis, C.S.; Karve, A.; Matiash, K.; Stone, T.; Li, J.X.; Wang, J.; Versteeg, H.; Aronow, B.; Ahmad, S.; Desai, P. & Bogdanov, V. (2021), Preclinical in vivo characterization of a first-in-class humanized antibody targeting alternatively spliced tissue factor., Cancer Research 81(13).
- Ettelaie, C.; Featherby, S.; Rondon, A.M.R.; Greenman, J.; Versteeg, H.H. & Maraveyas, A. (2021), De-palmitoylation of tissue factor regulates its activity, phosphorylation and cellular functions, Cancers 13(15).
- Kapteijn, M.Y.; Kaptein, F.H.J.; Stals, M.A.M.; Duinen, S.G. van; Taphoorn, M.J.B.; Dirven, L.; Koekoek, J.A.F.; Klok, F.A.; Versteeg, H.H. & Buijs, J.T. (2021), CDKN2A MUTATIONAL STATUS IS ASSOCIATED WITH VENOUS THROMBOEMBOLISM IN PATIENTS WITH GLIOBLASTOMA, Neuro-Oncology 23: 20-21.
- Wang, J.W.; Chong, S.Y.; Zharkova, O.; Yatim, S.M.J.M.; Wang, X.; Lim, X.C.; Huang, C.; Tan, C.Y.; Jiang, J.; Versteeg, H.H.; Dewerchin, M.; Carmeliet, P.; Lam, C.S.P. & Chan, M.Y. (2021), Tissue factor cytoplasmic domain exacerbates post-infarct left ventricular remodeling via orchestrating cardiac inflammation and angiogenesis, European Heart Journal 42: 3249-3249.
- Amaruddin, A.I.; Koopman, J.P.R.; Muhammad, M.; Versteeg, S.A.; Wahyuni, S.; Ree, R. van; Yazdanbakhsh, M.; Hamid, F. & Sartono, E. (2021), Bee- and wasp-venom sensitization in schoolchildren of high- and low-socioeconomic status living in an urban area of Indonesia, International Archives of Allergy and Immunology 182(11).
- Lewis, C.S.; Karve, A.; Matiash, K.; Stone, T.; Li, J.X.; Wang, J.K.; Versteeg, H.H.; Aronow, B.J.; Ahmad, S.A.; Desai, P.B. & Bogdanov, V.Y. (2021), A first-in-class, humanized antibody targeting alternatively spliced tissue factor, Frontiers in Oncology 11.
- Tilburg, J.; Coenen, D.M.; Zirka, G.; Dolleman, S.; Oeveren-Rietdijk, A.M. van; Karel, M.F.A.; Boer, H.C. de; Cosemans, J.M.E.M.; Versteeg, H.H.; Morange, P.E.; Vlijmen, B.J.M. van; Maracle, C.X. & Thomas, G.M. (2020), SLC44A2 deficient mice have a reduced response in stenosis but not in hypercoagulability driven venous thrombosis, Journal of Thrombosis and Haemostasis 18(7): 1714-1727.
- Najidh, S.; Versteeg, H.H. & Buijs, J.T. (2020), A systematic review on the effects of direct oral anticoagulants on cancer growth and metastasis in animal models, Thrombosis Research: Vascular Obstruction, Hemorrhage and Hemostasis 187: 18-27.
- Buijs, J.T. & Versteeg, H.H. (2020), Genes and proteins associated with the risk for cancer-associated thrombosis, Thrombosis Research: Vascular Obstruction, Hemorrhage and Hemostasis 191: S43-S49.
- Kroone, C.; Vos, M.; Rademakers, T.; Kuijpers, M.; Hoogenboezem, M.; Buul, J. van; Heemskerk, J.W.M.; Ruf, W.; Vlieg, A.V.; Versteeg, H.H.; Goumans, M.J.; Vries, C.J.M. de; Kurakula, K. & INVENT Consortium (2020), LIM-only protein FHL2 attenuates vascular tissue factor activity, inhibits thrombus formation in mice and FHL2 genetic variation associates with human venous thrombosis, Haematologica 105(6): 1677-1685.
- Tilburg, J.; Michaud, S.A.; Maracle, C.X.; Versteeg, H.H.; Borchers, C.H.; Vlijmen, B.J.M. van & Mohammed, Y. (2020), Plasma Protein Signatures of a Murine Venous Thrombosis Model and Slc44a2 Knockout Mice Using Quantitative-Targeted Proteomics, Thrombosis and Haemostasis 120(3): 423-436.
- Nieuwenhuizen, S.; Puijk, R.S.; Bemd, B. van den; Aldrighetti, L.; Arntz, M.; Boezem, P.B. van den; Bruynzeel, A.M.E.; Burgmans, M.C.; Cobelli, F. de; Coolsen, M.M.E.; Dejong, C.H.C.; Derks, S.; Diederik, A.; Duijvendijk, P. van; Eker, H.H.; Engelsman, A.F.; Erdmann, J.I.; Futterer, J.J.; Geboers, B.; Groot, G.; Haasbeek, C.J.A.; Janssen, J.J.; Jong, K.P. de; Kater, G.M.; Kazemier, G.; Kruimer, J.W.H.; Leclercq, W.K.G.; Leij, C. van der; Manusama, E.R.; Meier, M.A.J.; Meijs, B.B. van der; Melenhorst, M.C.A.M.; Nielsen, K.; Nijkamp, M.W.; Potters, F.H.; Prevoo, W.; Rietema, F.J.; Ruarus, A.H.; Ruiter, S.J.S.; Schouten, E.A.C.; Serafino, G.P.; Sietses, C.; Swijnenburg, R.J.; Timmer, F.E.F.; Versteeg, K.S.; Vink, T.; Vries, J.J.J. de; Wilt, J.H.W. de; Zonderhuis, B.M.; Scheffer, H.J.; Tol, P.M.P. van den & Meijerink, M.R. (2020), Resectability and ablatability criteria for the treatment of liver only colorectal metastases, Cancers 12(7).
- Hendriks, S.V.; Huisman, M.V.; Eikenboom, J.C.J.; Fogteloo, J.; Gelderblom, H.; Meer, F.J.M. van der; Stenger, W.J.E.; Verschoor, A.J.; Versteeg, H.H. & Klok, F.A. (2019), Home treatment of patients with cancer-associated venous thromboembolism, Thrombosis Research: Vascular Obstruction, Hemorrhage and Hemostasis 184: 122-128.
- Bos, M.H.A. & Versteeg, H.H. (2019), Snakebites and microvesicles: Popping bubbles, Research and Practice in Thrombosis and Haemostasis 3(2): 156-157.
- Klok, F.A.; Versteeg, H.H.; Verschoor, A.J. & Huisman, M.V. (2019), Comment on 'D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis', British Journal of Cancer 120(4): 472-472.
- Versteeg, H.H. & Rodger, M. (2019), Bugs in the system, Thrombosis Research 174: 166-166.
- Rondon, A.M.R.; Kroone, C.; Kapteijn, M.Y.; Versteeg, H.H. & Buijs, J.T. (2019), Role of Tissue Factor in Tumor Progression and Cancer-Associated Thrombosis, Seminars in Thrombosis and Hemostasis 45(4): 396-412.
- Rothmeier, A.S.; Versteeg, H.H. & Ruf, W. (2019), Factor VIIa-induced interaction with integrin controls the release of tissue factor on extracellular vesicles from endothelial cells, Journal of Thrombosis and Haemostasis 17(4): 627-634.
- Lewis, C.S.; Thomas, H.E.; Orr-Asman, M.A.; Green, L.C.; Boody, R.E.; Matiash, K.; Karve, A.; Hisada, Y.M.; Davis, H.W.; Qi, X.; Mercer, C.A.; Lucas, F.V.; Aronow, B.J.; Mackman, N.; Versteeg, H.H. & Bogdanov, V.Y. (2019), mTOR kinase inhibition reduces tissue factor expression and growth of pancreatic neuroendocrine tumors, Journal of Thrombosis and Haemostasis 17(1): 169-182.
- Mohammed, Y.; Kootte, R.S.; Kopatz, W.F.; Borchers, C.H.; Buller, H.R.; Versteeg, H.H.; Nieuwdorp, M. & Mens, T.E. van (2019), The intestinal microbiome potentially affects thrombin generation in human subjects, Journal of Thrombosis and Haemostasis.
- Heestermans, M.; Salloum-Asfar, S.; Streef, T.; Laghmani, E.; Salvatori, D.; Luken, B.M.; Zeerleder, S.S.; Spronk, H.M.H.; Korporaal, S.J.; Kirchhofer, D.; Wagenaar, G.T.M.; Versteeg, H.H.; Reitsma, P.H.; Renne, T. & Vlijmen, B.J.M. van (2019), Mouse venous thrombosis upon silencing of anticoagulants depends on tissue factor and platelets, not FXII or neutrophils, Blood 133(19): 2090-2099.
- Buijs, J.T.; Laghmani, E.; Akker, R.F.P. van den; Tieken, C.; Vletter, E.M.; Molen, K.M. van der; Crooijmans, J.J.; Kroone, C.; Devedec, S.E. le; Pluijm, G. van der & Versteeg, H.H. (2019), The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice, Journal of Thrombosis and Haemostasis 17(6): 951-963.
- Heestermans, M.; Jong, A. de; Tilburg, S. van; Reitsma, P.H.; Versteeg, H.H.; Spronk, H.M. & Vlijmen, B.J.M. van (2019), Use of "C9/11 Mismatch" Control Small Interfering RNA Reveals Sequence-Related Off-Target Effect on Coagulation of an Small Interfering RNA Targeting Mouse Coagulation Factor XII, Nucleic Acid Therapeutics: 1-6.
- Chu, G.; Versteeg, H.H.; Verschoor, A.J.; Trines, S.A.; Hemels, M.E.W.; Ay, C.; Huisman, M.V. & Klok, F.A. (2019), Atrial fibrillation and cancer - An unexplored field in cardiovascular oncology, Blood Reviews 35: 59-67.
- Kurakula, K.; Koenis, D.S.; Herzik, M.A.; Liu, Y.Y.; Craft, J.W.; Loenen, P.B. van; Vos, M.; Tran, M.K.; Versteeg, H.H.; Goumans, M.J.T.H.; Ruf, W.; Vries, C.J.M. de & Sen, M. (2018), Structural and cellular mechanisms of peptidyl-prolyl isomerase Pin1-mediated enhancement of Tissue Factor gene expression, protein half-life, and pro-coagulant activity, Haematologica 103(6): 1073-1082.
- Bergmeier, W.; Antoniak, S.; Conway, E.M.; Denis, C.V.; George, L.A.; Isermann, B.; Key, N.S.; Krishnaswamy, S.; Lam, W.A.; Lillicrap, D.; Liu, J.; Looney, M.R.; Lopez, J.A.; Maas, C.; Peyvandi, F.; Ruf, W.; Sood, A.K.; Versteeg, H.H.; Wolberg, A.S.; Wong, P.C.; Wood, J.P. & Weiler, H. (2018), Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis, Research and Practice in Thrombosis and Haemostasis 2(3): 407-428.
- Versteeg, H.H. & Rodger, M. (2018), HAPPY NEW CAREER!!, Thrombosis Research 162: 87-87.
- Tilburg, J.; Adili, R.; Nair, T.S.; Hawley, M.E.; Tuk, D.C.; Jackson, M.; Spronk, H.M.; Versteeg, H.H.; Carey, T.E.; Vlijmen, B.J.M. van; Maracle, C.X. & Holinstat, M. (2018), Characterization of hemostasis in mice lacking the novel thrombosis susceptibility gene Slc44a2, Thrombosis Research 171: 155-159.
- Unlu, B. & Versteeg, H.H. (2018), Cancer-associated thrombosis: The search for the holy grail continues, Research and Practice in Thrombosis and Haemostasis 2(4): 622-629.
- Paauwe, M.; Schoonderwoerd, M.J.A.; Helderman, R.F.C.P.; Harryvan, T.J.; Groenewoud, A.; Pelt, G.W. van; Bor, R.; Hemmer, D.M.; Versteeg, H.H.; Snaar-Jagalska, B.E.; Theuer, C.P.; Hardwick, J.C.H.; Sier, C.F.M.; Dijke, P. ten & Hawinkels, L.J.A.C. (2018), Endoglin Expression on Cancer-Associated Fibroblasts Regulates Invasion and Stimulates Colorectal Cancer Metastasis, Clinical Cancer Research 24(24): 6331-6344.
- Wang, J.W.; Zhang, Y.N.; Sze, S.K.; Weg, S.M. van de; Vernooij, F.; Schoneveld, A.H.; Tan, S.H.; Versteeg, H.H.; Timmers, L.; Lam, C.S.P. & Kleijn, D.P.V. de (2018), Lowering Low-Density Lipoprotein Particles in Plasma Using Dextran Sulphate Co-Precipitates Procoagulant Extracellular Vesicles, International Journal of Molecular Sciences 19(1).
- Unlu, B.; Es, N. van; Arindrarto, W.; Kielbasa, S.M.; Mei, H.; Westerga, J.; Middeldorp, S.; Kuppen, P.J.K.; Otten, J.M.M.B.; Cannegieter, S. & Versteeg, H.H. (2018), Genes associated with venous thromboembolism in colorectal cancer patients, Journal of Thrombosis and Haemostasis 16(2): 293-302.
- Rondon, A.M.D.; Almeida, V.H. de; Gomes, T.; Vercoza, B.R.F.; Carvalho, R.S.; Konig, S.; Rodrigues, J.C.F.; Mermelstein, C.D.; Versteeg, H.H. & Monteiro, R.Q. (2018), Tissue factor mediates microvesicles shedding from MDA-MB-231 breast cancer cells, Biochemical and Biophysical Research Communications 502(1): 137-144.
- Versteeg, H.H. & Rodger, M. (2018), It's all in your genes, Thrombosis Research 169: 157-157.
- Morrow, J.J.; Bayles, I.; Funnell, A.P.W.; Miller, T.E.; Saiakhova, A.; Lizardo, M.M.; Bartels, C.F.; Kapteijn, M.Y.; Hung, S.; Mendoza, A.; Dhillon, G.; Chee, D.R.; Myers, J.T.; Allen, F.; Gambarotti, M.; Righi, A.; Difeo, A.; Rubin, B.P.; Huang, A.Y.; Meltzer, P.S.; Helman, L.J.; Picci, P.; Versteeg, H.H.; Stamatoyannopoulos, J.A.; Khanna, C. & Scacheri, P.C. (2018), Positively selected enhancer elements endow osteosarcoma cells with metastatic competence, Nature Medicine 24(2): 176-+.
- Kurakula, K.; Koenis, D.S.; Herzik, M.A.; Liu, Y.Y.; Craft, J.W.; Loenen, P.B. van; Vos, M.; Tran, M.K.; Versteeg, H.H.; Goumans, M.J.T.H.; Ruf, W.; Vries, C.J.M. de & Sen, M. (2018), Structural and cellular mechanisms of peptidyl-prolyl isomerase Pin1-mediated enhancement of Tissue Factor gene expression, protein half-life, and pro-coagulant activity, Haematologica 103(6): 1073-1082.
- Shaker, H.; Harrison, H.; Clarke, R.; Landberg, G.; Bundred, N.J.; Versteeg, H.H. & Kirwan, C.C. (2017), Tissue Factor promotes breast cancer stem cell activity in vitro, Oncotarget 8(16): 25915-25927.
- Swier, N. & Versteeg, H.H. (2017), Reciprocal links between venous thromboembolism, coagulation factors and ovarian cancer progression, Thrombosis Research 150: 8-18.
- Versteeg, H.H. & Rodger, M. (2017), Insane in the membrane, insane in the brain!, Thrombosis Research 152: 98-98.
- Unlu, B.; Bogdanov, V.Y. & Versteeg, H.H. (2017), Interplay between alternatively spliced Tissue Factor and full length Tissue Factor in modulating coagulant activity of endothelial cells, Thrombosis Research 156: 1-7.
- Unruh, D.; Unlu, B.; Lewis, C.S.; Qi, X.Y.; Chu, Z.T.; Sturm, R.; Keil, R.; Ahmad, S.A.; Sovershaev, T.; Adam, M.; Dreden, P. van; Woodhams, B.J.; Ramchandani, D.; Weber, G.F.; Rak, J.W.; Wolberg, A.S.; Mackman, N.; Versteeg, H.H. & Bogdanov, V.Y. (2016), Antibody-based targeting of alternatively spliced tissue factor: a new approach to impede the primary growth and spread of pancreatic ductal adenocarcinoma, Oncotarget 7(18): 25264-25275.
- Tieken, C.; Verboom, M.C.; Ruf, W.; Gelderblom, H.; Bovee, J.V.M.G.; Reitsma, P.H.; Cleton-Jansen, A.M. & Versteeg, H.H. (2016), Tissue factor associates with survival and regulates tumour progression in osteosarcoma, Thrombosis and Haemostasis 115(5): 1025-1033.
- Tieken, C. & Versteeg, H.H. (2016), Anticoagulants versus cancer, Thrombosis Research 140: S148-S153.
- Kooiman, J.; Exter, P.L. den; Kilicsoy, I.; Cannegieter, S.C.; Eikenboom, J.; Huisman, M.V.; Klok, F.A. & Versteeg, H.H. (2015), Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism, Journal of Thrombosis and Thrombolysis 40(3): 323-330.
- Versteeg, H.H. (2015), Tissue Factor: Old and New Links with Cancer Biology, Seminars in Thrombosis and Hemostasis 41(7): 747-755.
- Bogdanov, V.Y. & Versteeg, H.H. (2015), "Soluble Tissue Factor" in the 21st Century: Definitions, Biochemistry, and Pathophysiological Role in Thrombus Formation, Seminars in Thrombosis and Hemostasis 41(7): 700-707.
- Kocaturk, B.; Tieken, C.; Vreeken, D.; Unlu, B.; Engels, C.C.; Kruijf, E.M. de; Kuppen, P.J.; Reitsma, P.H.; Bogdanov, V.Y. & Versteeg, H.H. (2015), Alternatively spliced tissue factor synergizes with the estrogen receptor pathway in promoting breast cancer progression, Journal of Thrombosis and Haemostasis 13(9): 1683-1693.
- Spek, C.A.; Versteeg, H.H. & Borensztajn, K.S. (2015), Anticoagulant therapy of cancer patients: Will patient selection increase overall survival?, Thrombosis and Haemostasis 114(3): 530-536.
- Kocaturk Begum & Versteeg Henri H. (2015), Orthotopic Injection of Breast Cancer Cells into the Mammary Fat Pad of Mice to Study Tumor Growth, Journal of Visualized Experiments.
- Bijkerk, R.; Solingen, C. van; Boer, H.C. de; Pol, P. van der; Khairoun, M.; Bruin, R.G. de; Oeveren-Rietdijk, A.M. van; Lievers, E.; Schlagwein, N.; Gijlswijk, D.J. van; Roeten, M.K.; Neshati, Z.; Vries, A.A.F. de; Rodijk, M.; Pike-Overzet, K.; Berg, Y.W. van den; Veer, E.P. van der; Versteeg, H.H.; Reinders, M.E.J.; Staal, F.J.T.; Kooten, C. van; Rabelink, T.J. & Zonneveld, A.J. van (2014), Hematopoietic overexpression of miR-126 promotes vasculogenesis and protects against renal ischemia reperfusion injury by promoting vascular integrity, Angiogenesis 17(3): 765-765.
- Unu, B. & Versteeg, H.H. (2014), Effects of tumor-expressed coagulation factors on cancer progression and venous thrombosis: is there a key factor?, Thrombosis Research 133: S76-S84.
- Bijkerk, R.; Solingen, C. van; Boer, H.C. de; Pol, P. van der; Khairoun, M.; Bruin, R.G. de; Oeveren-Rietdijk, A.M. van; Lievers, E.; Schlagwein, N.; Gijlswijk, D.J. van; Roeten, M.K.; Neshati, Z.; Vries, A.A.F. de; Rodijk, M.; Pike-Overzet, K.; Berg, Y.W. van den; Veer, E.P. van der; Versteeg, H.H.; Reinders, M.E.J.; Staal, F.J.T.; Kooten, C. van; Rabelink, T.J. & Zonneveld, A.J. van (2014), eHematopoietic MicroRNA-126 Protects against Renal Ischemia/Reperfusion Injury by Promoting Vascular Integrity, Journal of the American Society of Nephrology 25(8): 1710-1722.
- Unruh, D.; Turner, K.; Srinivasan, R.; Kocaturk, B.; Qi, X.Y.; Chu, Z.T.; Aronow, B.J.; Plas, D.R.; Gallo, C.A.; Kalthoff, H.; Kirchhofer, D.; Ruf, W.; Ahmad, S.A.; Lucas, F.V.; Versteeg, H.H. & Bogdanov, V.Y. (2014), Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma, International Journal of Cancer 134(1): 9-20.
- Timp, J.; Timp, J.F.; Lijfering, W.M.; Rosendaal, F.R.; Versteeg, H.H. & Cannegieter, S.C. (2013), The risk of venous thrombosis in patients with malignancy is largely mediated through levels of factor VIII and von Willebrand factor, Journal of Thrombosis and Haemostasis 11: 93-94.
- Kocaturk, B.; Berg, Y.W. van den; Tieken, C.; Kuppen, P.J.K.; Ruf, W.; Reitsma, P.H.; Osanto, S.; Bogdanov, V.Y. & Versteeg, H.H. (2013), Alternatively spliced Tissue Factor fuels breast cancer growth by binding to a non-canonical site on beta1 integrins, Journal of Thrombosis and Haemostasis 11: 74-74.
- Hengel, L.G. van den; Hellingman, A.A.; Nossent, A.Y.; Oeveren-Rietdijk, A.M. van; Vries, M.R. de; Spek, C.A.; Zonneveld, A.J. van; Reitsma, P.H.; Hamming, J.F.; Boer, H.C. de; Versteeg, H.H. & Quax, P.H.A. (2013), Protease-Activated Receptor (PAR)2, but Not PAR1, Is Involved in Collateral Formation and Anti-Inflammatory Monocyte Polarization in a Mouse Hind Limb Ischemia Model, PLoS ONE 8(4).
- Versteeg, H.H. & Ruf, W. (2013), New helpers in TF-dependent migration, Journal of Thrombosis and Haemostasis 11(10): 1877-1879.
- Safdar, H.; Cheung, K.L.; Salvatori, D.; Versteeg, H.H.; Laghmani, E.; Wagenaar, G.T.M.; Reitsma, P.H. & Vlijmen, B.J.M. van (2013), Acute and severe coagulopathy in adult mice following silencing of hepatic antithrombin and protein C production, Blood 121(21): 4413-4416.
- Hengel, L.G. van den; Steijn-van Tol, A.Q.M.J. van; Bertina, R.M.; Versteeg, H.H. & Osanto, S. (2013), Microparticle-associated tissue factor activity in plasma is unaffected by cytolytic chemotherapy treatment in metastatic testicular cancer patients, Thrombosis Research 131(2): 187-189.
- Hengel, L.G. van den; Osanto, S.; Reitsma, P.H. & Versteeg, H.H. (2013), Murine tissue factor coagulant activity is critically dependent on the presence of an intact allosteric disulfide, Haematologica 98(1): 153-158.
- Kocaturk, B.; Berg, Y.W. van den; Tiekena, C.; Mieog, J.S.D.; Kruijf, E.M. de; Engels, C.C.; Ent, M.A. van der; Kuppen, P.J.; Velde, C.J. van de; Ruf, W.; Reitsma, P.H.; Osanto, S.; Liefers, G.J.; Bogdanov, V.Y. & Versteeg, H.H. (2013), Alternatively spliced tissue factor promotes breast cancer growth in a beta 1 integrin-dependent manner, Proceedings of the National Academy of Sciences 110(28): 11517-11522.
- Kocaturk, B. & Versteeg, H.H. (2013), Tissue factor-integrin interactions in cancer and thrombosis: every Jack has his Jill, Journal of Thrombosis and Haemostasis 11: 285-293.
- Timp, J.F.; Braekkan, S.K.; Versteeg, H.H. & Cannegieter, S.C. (2013), Epidemiology of cancer-associated venous thrombosis, Blood 122(10): 1712-1723.
- Versteeg, H.H.; Heemskerk, J.W.M.; Levi, M. & Reitsma, P.H. (2013), NEW FUNDAMENTALS IN HEMOSTASIS, Physiological Reviews 93(1): 327-358.
- Reitsma, P.H.; Versteeg, H.H. & Middeldorp, S. (2012), Mechanistic View of Risk Factors for Venous Thromboembolism, Arteriosclerosis, Thrombosis, and Vascular Biology 32(3): 563-568.
- Tieken, C.; Berg, Y.W. van den; Kruijf, E.M. de; Kuppen, P.J.K.; Reitsma, P.H.; Bogdanov, V.Y. & Versteeg, H.H. (2012), Interplay of tissue factor splice variants in thrombosis, Thrombosis Research 129: S169-S169.
- Hengel, L.G. van den; Berg, Y.W. van den; Reitsma, P.H.; Bos, M.H.A. & Versteeg, H.H. (2012), Evolutionary conservation of the tissue factor disulfide bonds and identification of a possible oxidoreductase binding motif.
- Kocaturk, B.; Tieken, C.; Reitsma, P.H.; Bogdanov, V.Y. & Versteeg, H.H. (2012), Alternatively spliced tissue factor triggers breast tumor growth, Thrombosis Research 129: S168-S169.
- Berg, Y.W. van den; Osanto, S.; Reitsma, P.H. & Versteeg, H.H. (2012), The relationship between tissue factor and cancer progression: insights from bench and bedside, Blood 119(4): 924-932.
- Godby, R.C.; Berg, Y.W. van den; Srinivasan, R.; Sturm, R.; Hui, D.Y.; Konieczny, S.F.; Aronow, B.J.; Ozhegov, E.; Ruf, W.; Versteeg, H.H. & Bogdanov, V.Y. (2012), Nonproteolytic Properties of Murine Alternatively Spliced Tissue Factor: Implications for Integrin-Mediated Signaling in Murine Models, Molecular Medicine 18(5): 771-779.
- Kocaturk, B. & Versteeg, H.H. (2012), Tissue factor isoforms in cancer and coagulation: May the best isoform win, Thrombosis Research 129: S69-S75.
- Hengel, L.G. van den; Hellingman, A.A.; Boer, H.C. de; Oeveren-Rietdijk, A.M. van; Spek, C.A.; Zonneveld, A.J. van; Reitsma, P.H.; Hamming, J.F.; Quax, P.H.A. & Versteeg, H.H. (2011), PAR-2, but not PAR-1, is critically involved in collateral formation in a mouse hind limb ischemia model, Journal of Thrombosis and Haemostasis 9: 953-953.
- Berg, Y.W. van den; Mieog, J.S.D.; Kruijf, E.M. de; Wang, J.; Sajet, A.; Kuppen, P.J.K.; Velde, C.J.H. van de; Reitsma, P.H.; Osanto, S.; Bogdanov, V.Y. & Versteeg, H.H. (2011), Alternatively spliced and full-length tissue factor reveal a non-identical relationship to clinicopathological parameters in a large cohort of human breast cancer, Journal of Thrombosis and Haemostasis 9: 803-803.
- van den Hengel LG & Versteeg HH (2011), Tissue factor signaling: a multi-faceted function in biological processes., Frontiers in bioscience (Scholar edition) 3: 1500-10.
- Srinivasan, R.; Ozhegov, E.; Berg, Y.W. van den; Aronow, B.J.; Franco, R.S.; Palascak, M.B.; Fallon, J.T.; Ruf, W.; Versteeg, H.H. & Bogdanov, V.Y. (2011), Splice variants of tissue factor promote monocyte-endothelial interactions by triggering the expression of cell adhesion molecules via integrin-mediated signaling.
- Versteeg, H.H. & Ruf, W. (2011), Thiol pathways in the regulation of tissue factor prothrombotic activity, Current Opinion in Hematology 18(5): 343-348.
- Hengel, L.G. van den; Kocaturk, B.; Reitsma, P.H.; Ruf, W. & Versteeg, H.H. (2011), Complete abolishment of coagulant activity in monomeric disulfide-deficient tissue factor, Blood 118(12): 3446-+.
- Queiroz, K.C.S.; van't Veer, C.; Berg, Y. van den; Duitman, J.W.; Versteeg, H.H.; Aberson, H.L.; Groot, A.P.; Verstege, M.I.; Roelofs, J.J.T.H.; Velde, A.A.T. & Spek, C.A. (2011), Tissue factor-dependent chemokine production aggravates experimental colitis.
- Hengel, L.G. van den; Berg, Y.W. van den; Reitsma, P.H.; Bos, M.H.A. & Versteeg, H.H. (2011), Evolutionary Conservation of the Tissue Factor Disulfide Bonds and Identification of a Possible Oxidoreductase Binding Motif., Journal of Thrombosis and Haemostasis.
- Queiroz, K.C.S.; Veer, C. van 't; Berg, Y. van den; Duitman, J.; Versteeg, H.H.; Aberson, H.L.; Groot, A.P.; Verstege, M.I.; Roelofs, J.J.T.H.; Velde, A.A.T. & Spek, C.A. (2011), Tissue Factor-Dependent Chemokine Production Aggravates Experimental Colitis, Molecular Medicine 17(9-10): 1119-1126.
- Schaffner, F.; Versteeg, H.H.; Schillert, A.; Yokota, N.; Petersen, L.C.; Mueller, B.M. & Ruf, W. (2010), Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development, Blood 116(26): 6106-6113.
- Berg, Y.W. van den & Versteeg, H.H. (2010), Alternatively spliced tissue factor A crippled protein in coagulation or a key player in non-haemostatic processes?, H�mostaseologie 30(3): 144+.
- Berg, Y.W. van den & Versteeg, H.H. (2010), Alternatively spliced tissue factor. A crippled protein in coagulation or a key player in non-haemostatic processes?, H�mostaseologie 30(3): 144-9.
- Srinivasan, R.; Ozhegov, E.; Berg, Y. van den; Versteeg, H.H. & Bogdanov, V. (2010), Human Alternatively Spliced Tissue Factor Promotes Monocyte-Endothelial Interactions Via Upregulation of Adhesion Molecules In Microvascular Endothelial Cells, Blood 116(21): 155-155.
- Godby, R.; Berg, Y. van den; Srinivasan, R.; Ozhegov, E.; Versteeg, H.H. & Bogdanov, V. (2010), Evaluation of Non-Proteolytic Functions of Murine Alternatively Spliced Tissue Factor, Blood 116(21): 492-492.
- van den Berg YW, van den Hengel LG, Myers HR, Ayachi O, Jordanova E, Ruf W, Spek CA, Reitsma PH, Bogdanov VY & Versteeg HH (2009), Alternatively spliced tissue factor induces angiogenesis through integrin ligation, Proceedings of the National Academy of Sciences 106(46): 19497-19502.
- Niers TMH, Bruggemann LW, Van Sluis GL, Liu RD, Versteeg HH, Buller HR, Van Noorden CJF, Reitsma PH, Spek CA & Richel DJ (2009), Long-term thrombin inhibition promotes cancer cell extravasation in a mouse model of experimental metastasis, Journal of Thrombosis and Haemostasis 7(9): 1595-1597.
- Versteeg HH, Borensztajn KS, Kerver ME, Ruf W, Reitsma PH, Spek CA & Peppelenbosch MP (2008), TF : FVIIa-specific activation of CREB upregulates proapoptotic proteins via protease-activated receptor-2, Journal of Thrombosis and Haemostasis 6(9).
- Bruggemann LW, Versteeg HH, Reitsma PH & Spek CA (2008), High factor VIIa levels do not promote tumor metastasis, Thrombosis and Haemostasis 99(4).
- Selectiecommissie
- Selectiecommissie
- Editorial duties